Therapeutic pharmaceuticals (drugs) have witnessed a sea change in recent years. The large, dominant group of drugs derived from synthetic, small molecules has been joined by a new type of drug that has been very effective with diseases that were previously untreatable. These biopharmaceuticals include monoclonal antibodies (mAbs), proteins that are produced (cloned) in large quantities using recombinant
MestReNova, scientific processing and analysis software produced by Mestrelab, has a long reputation for ease-of-use, combined with powerful processing and analysis capabilities for NMR, UV-IR, and LC-MS.
In collaboration with key individuals from Bruker Biospin, we set out in early 2019 to produce a suite of new capabilities that will meet many of the analytical needs for mAb analysis using 2D NMR spectral data.Application Note_final3